for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Syneos Health Inc

SYNH.OQ

Latest Trade

55.05USD

Change

0.13(+0.24%)

Volume

7,999

Today's Range

54.75

 - 

55.10

52 Week Range

36.49

 - 

56.27

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
54.92
Open
55.05
Volume
7,999
3M AVG Volume
8.90
Today's High
55.10
Today's Low
54.75
52 Week High
56.27
52 Week Low
36.49
Shares Out (MIL)
103.46
Market Cap (MIL)
5,683.41
Forward P/E
17.36
Dividend (Yield %)
--

Next Event

Q3 2019 Syneos Health Inc Earnings Release

Latest Developments

More

Syneos Health Says SEC Does Not Intend To Recommend An Enforcement Action Against Co

Syneos Health Posts Quarterly EPS Of $0.11

Syneos Health Reports Q2 Earnings Per Share $0.11

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Syneos Health Inc

Syneos Health, Inc., formerly INC Research Holdings, Inc., is a global contract research organization (CRO). The Company focuses on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company operates through two segments: Clinical Development Services and Phase I Services. The Company's Clinical Development Services segment offers a range of clinical development services, including full-service global studies, as well as ancillary services, such as clinical monitoring, investigator recruitment, patient recruitment, data management, study reports to assist customers with their drug development process, quality assurance audits and specialized consulting services. The Phase I Services segment focuses on clinical development services for Phase I trials, which include scientific exploratory medicine, first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds.

Industry

Biotechnology & Drugs

Contact Info

1030 Sync Street

+1.919.8769300

https://www.syneoshealth.com/

Executive Leadership

John M Dineen

Independent Chairman of the Board

Paul D. Colvin

President - Clinical Solutions

Alistair Macdonald

Chief Executive Officer, Director

Jason Meggs

Chief Financial Officer

Lisa van Capelle

Chief Human Resource Officer

Key Stats

2.08 mean rating - 13 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

1.0K

2017

1.9K

2018

4.4K

2019(E)

4.7K
EPS (USD)

2016

2.500

2017

2.270

2018

2.870

2019(E)

3.163
Price To Earnings (TTM)
434.53
Price To Sales (TTM)
1.25
Price To Book (MRQ)
2.01
Price To Cash Flow (TTM)
20.34
Total Debt To Equity (MRQ)
98.40
LT Debt To Equity (MRQ)
90.77
Return on Investment (TTM)
0.27
Return on Equity (TTM)
0.21

Latest News

BRIEF-Syneos Health Reports Q1 Adjusted Earnings Per Share Of $0.55

* Q1 EARNINGS PER SHARE VIEW $0.51 -- THOMSON REUTERS I/B/E/S

BRIEF-Syneos Health Appoints Jason Meggs As Interim CFO

* SYNEOS HEALTH SAYS APPOINTED JASON MEGGS AS EXECUTIVE VICE PRESIDENT AND INTERIM CHIEF FINANCIAL OFFICER OF CO EFFECTIVE IMMEDIATELY - SEC FILING Source text: (http://bit.ly/2sO58iC) Further company coverage:

BRIEF-Syneos Health Names Lisa van Capelle Chief Human Resources Officer

* SYNEOS HEALTH NAMES LISA VAN CAPELLE CHIEF HUMAN RESOURCES OFFICER Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up